Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 30 (11), 1577-83

Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy After Liver Transplantation

Affiliations

Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy After Liver Transplantation

Hyeyoung Kim et al. J Korean Med Sci.

Abstract

Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is universal and progressive. Here, we report recent results of response-guided therapy for HCV recurrence based on early protocol biopsy after LT. We reviewed patients who underwent LT for HCV related liver disease between 2010 and 2012. Protocol biopsies were performed at 3, 6, and 12 months after LT in HCV recurrence (positive HCV-RNA). For any degree of fibrosis, ≥ moderate inflammation on histology or HCV hepatitis accompanying with abnormal liver function, we treated with pegylated interferon and ribavirin. We adjusted treatment period according to individual response to treatment. Among 41 HCV related recipients, 25 (61.0%) who underwent protocol biopsies more than once were enrolled in this study. The mean follow-up time was 43.1 (range, 23-55) months after LT. Genotype 1 and 2 showed in 56.0% and 36.0% patients, respectively. Of the 25 patients, 20 (80.0%) started HCV treatment after LT. Rapid or early virological response was observed in 20 (100%) patients. Fifteen (75.0%) patients finished the treatment with end-of-treatment response. Sustained virological response (SVR) was in 11 (55.0%) patients, including 5 (41.7%) of 12 genotype 1 and 6 (75.0%) of 8 non-genotype 1 (P = 0.197). Only rapid or complete early virological response was a significant predictor for HCV treatment response after LT (100% in SVR group vs. 55.6% in non-SVR group, P = 0.026). Overall 3-yr survival rate was 100%. In conclusion, response-guided therapy for HCV recurrence based on early protocol biopsy after LT shows encouraging results.

Keywords: Biopsy; Hepatitis C; Liver Transplantation; Recurrence; Therapeutics.

Conflict of interest statement

DISCLOSURE: The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Results of early protocol biopsies in hepatitis C virus related recipient after liver transplantation. HCV, hepatitis C virus; LT, liver transplantation.
Fig. 2
Fig. 2. Outcome of response-guided therapy for hepatitis C virus. HCV, hepatitis C virus; Tx., treatment; RVR, rapid virological response; EVR, early virological response; ETR, end-of-treatment response; SVR, sustained virological response.

Similar articles

See all similar articles

References

    1. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–820. - PubMed
    1. Agarwal K, Barnabas A. Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis. 2013;45:S349–S354. - PubMed
    1. Lange CM. The importance of IL28B genotype in hepatitis C virus-associated liver transplantation. Liver Int. 2013;33:169–171. - PubMed
    1. Rubin A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:805–812. - PubMed
    1. Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". Am J Transplant. 2014;14:994–1002. - PubMed

Substances

Feedback